all news

Our partners are building great companies. We love to share their stories.

Tue, 29 Nov 2022 Medical Marketing & Media

AstraZeneca expands oncology portfolio with $320M deal for Neogene Therapeutics

Tue, 15 Nov 2022 BioSpace

Roche Doubles Down on Jnana's RAPID Platform in $2B Deal

Thu, 10 Nov 2022

Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors

Mon, 7 Nov 2022

Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to 'Off-the-Shelf' CAR-T Platform

Fri, 4 Nov 2022 Drug Discovery and Development

PathAI presents data on using AI to aid liver research and NASH drug development

Mon, 24 Oct 2022 PR Newswire

Cohere Health and Humana Expand Partnership to Further Improve Physician and Member Experiences

Thu, 20 Oct 2022

AgBiome receives EPA approval for new Esendo™ fungicide

Tue, 18 Oct 2022 GlobeNewswire

Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia

Mon, 17 Oct 2022 Business Insider

Polaris Managing Partner Amy Schulman Named by Business Insider as "Top Pioneer in Biotech VC"

Wed, 12 Oct 2022 MobiHealthNews

Folx Health scores $30M to add mental health support

Tue, 11 Oct 2022 PR Newswire (EN)

Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson's Research

Tue, 11 Oct 2022

Neumora Therapeutics Announces $112 Million Series B Financing

Thu, 6 Oct 2022 PR Newswire

OSF HealthCare Partnering with US HealthVest on new behavioral health hospital

Mon, 26 Sep 2022

American Diabetes Association, Podimetrics and Abbott collaborate to prevent diabetic foot amputations

Fri, 16 Sep 2022 Fortune

PathAI Named to Fortune 2022 Best Workplaces in Biotechnology and Pharmaceuticals

Wed, 14 Sep 2022 BioSpace

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 202

Wed, 14 Sep 2022

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

Wed, 7 Sep 2022

AgBiome announces collaboration with W. L. Gore & Associates

Wed, 7 Sep 2022 Freenome

Freenome Launches Study of Multiple Cancers Pairing Multiomics with Real-World Data — Freenome

Thu, 25 Aug 2022

PathAI and Bristol Myers Squibb extend AI partnership

Wed, 24 Aug 2022 Fast Company

LGBTQIA+ healthcare provider FOLX health launches Monkeypox services

Wed, 24 Aug 2022 BioSpace

Tessa Taps Ex-Takeda Exec to Propel CAR-T Assets Foward | BioSpace

Mon, 15 Aug 2022 Axios

Oui Therapeutics eyes platform potential for suicide prevention app

Mon, 15 Aug 2022 PathAI

PathAI Receives Both FDA 510(k) Clearance and CE Mark for AISightTM Dx Platform | PathAI

Thu, 21 Jul 2022

Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives

Wed, 20 Jul 2022 GlobeNewswire

Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-base

Wed, 20 Jul 2022

CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Progra

Tue, 12 Jul 2022 FDAREG Watch - Press Release

Geisinger and Cohere Health Join in Driving High-Value Care and Reducing Provider Burden

Tue, 12 Jul 2022 Pittsburgh Post-Gazette

Siblings open ByHeart baby formula plant, feeding acute U.S. shortage

Tue, 28 Jun 2022

Vertafore Acquires MGA Systems, Expanding and Enhancing Solutions for MGAs

This website is not an advertisement. This website is intended solely to provide general business information on Polaris Partners and any affiliates thereof (collectively, “Polaris”). Nothing on this website should be construed as an offer of investment advisory services by Polaris or a solicitation or an offer of interests in any Polaris fund. Visitors to this website are not to construe the contents of this website or any prior or subsequent communication from Polaris or any of its representatives, as legal, tax or investment advice. References to specific companies are for illustrative purposes only and do not represent all of the companies recommended for advisory clients. Such references are not intended to be, and should not be interpreted as, recommendations or investment advice. All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed, and Polaris disclaims any duty to update any of the information and data contained herein. Certain statements may be deemed forward-looking, but any such statements are not guarantees of any future performance and actual results or developments may differ materially from those discussed. There is no guarantee that investment objectives will be achieved or that any particular investment will be profitable. Past performance does not guarantee future results. Where applicable, figures include investments made directly and indirectly by the Polaris Main Funds and may include co-investments with the Polaris Growth Funds and the Polaris Innovation Funds. Please see the complete list of investments here, as well as the Terms of Use for additional information and disclosures.


The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.